CreditReports.dk
HomeScreen companies

PHARMA-TRADE A/S Financials, key figures and credit report

CVR number: 87339815 Established 1984 Industry: 20 Manufacture of chemicals and chemical products
Company contact details
Skaaremosevej 11-14, Blistrup 3230 Græsted rsa@persano.dk
Net sales 325.1 mDKK FY 2025 -14.9% vs 2024
EBIT margin 8.5 % FY 2025 -6 pp vs 2024
Net debt 3.8 mDKK FY 2025 +140.9% vs 2024
Quick ratio 3.9 FY 2025 -0.8 vs 2024

Income statement (mDKK)

2021
2022
2023
2024
2025
Fiscal period length1212121212
Net sales366.15337.74374.75382.24325.13
Other operating income0.070.060.000.20
Costs of manufacturing- 252.67- 245.89- 274.80- 267.54- 235.25
Gross profit113.4891.8599.95114.7089.88
Costs of management-50.30-51.15-51.22-54.23-58.34
Costs of distribution-3.73-4.08-4.04-5.08-4.13
EBIT59.5236.6744.6955.3827.60
Other financial income0.110.281.161.730.73
Other financial expenses-2.42-2.14-1.80-1.78-1.25
Reduction non-current investment assets-0.21-0.21-0.21
Pre-tax profit57.0034.5943.8555.3427.09
Income taxes-10.56-6.58-9.49-12.20-5.85
Net earnings46.4428.0134.3543.1421.23

Assets (mDKK)

2021
2022
2023
2024
2025
Goodwill0.420.21
Intangible assets total0.420.21
Land and waters76.6572.7869.0775.0270.76
Buildings37.3237.1336.0034.0734.42
Machinery and equipment1.781.541.921.943.13
Advance payments and construction in progress3.323.992.645.0112.21
Tangible assets total119.07115.44109.63116.04120.52
Investments total0.170.170.170.170.17
Non-current loans receivable0.530.670.660.650.58
Non-current other receivables0.520.06
Long term receivables total0.531.190.730.650.58
Semifinished products4.535.115.796.046.88
Raw materials and consumables65.6179.8269.9263.6760.50
Finished products/goods17.0519.1422.7725.1732.94
Inventories total87.19104.0898.4894.88100.33
Current trade debtors77.5487.0676.7094.9775.87
Prepayments and accrued income0.410.261.270.160.54
Current other receivables0.090.060.420.130.03
Current deferred tax assets1.521.801.58
Short term receivables total79.5789.1978.3995.2678.03
Cash and bank deposits54.7914.1649.7643.2927.22
Cash and cash equivalents54.7914.1649.7643.2927.22
Balance sheet total (assets)341.73324.43337.16350.28326.83

Equity and liabilities (mDKK)

2021
2022
2023
2024
2025
Share capital3.003.003.003.003.00
Asset revaluation reserve20.5919.4618.3424.7723.15
Shares repurchased40.0020.0030.0040.0020.00
Other reserves2.7510.399.33
Retained earnings129.65157.22156.35161.88186.63
Profit of the financial year46.4428.0134.3543.1421.23
Shareholders equity total242.44238.09251.38272.79254.02
Provisions15.0714.7814.5016.7217.56
Non-current loans from credit institutions39.6536.4534.1231.0127.77
Non-current other liabilities10.96
Non-current deferred tax liabilities1.682.59
Non-current liabilities total50.6038.1436.7131.0127.77
Current loans from credit institutions3.363.242.793.093.21
Advances received0.300.240.360.44
Current trade creditors22.0426.8428.7720.4519.93
Short-term deferred tax liabilities0.260.21
Other non-interest bearing current liabilities7.913.352.515.663.91
Current liabilities total33.6233.4334.5729.7727.49
Balance sheet total (liabilities)341.73324.43337.16350.28326.83
Page generated